High Definition Transcranial Direct Current Stimulation (HD-tDCS) for Early Alzheimer's Disease (HD-tDCS)
Primary Purpose
Transcranial Direct Current Stimulation, Functional Magnetic Resonance Imaging, Early Alzheimer's Disease
Status
Recruiting
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
HD-tDCS
computer-based cognitive training
Sponsored by
About this trial
This is an interventional basic science trial for Transcranial Direct Current Stimulation focused on measuring High Definition Transcranial Direct Current Stimulation, Functional Magnetic Resonance Imaging, Neuropsychology, Early Alzheimer's Disease, Working Memory, Alzheimer's Disease Assessment Scale-Cognitive Subscale
Eligibility Criteria
Inclusion Criteria:
- Subject diagnosed with early Alzheimer's disease or related diseases according to NINCDS-ACDRADA criteria.
- Subjects must have a MMSE score between 10 and 27,indicating mild cognitive impairment or dementia
- CDR score ≤ 2
- Subject under treatment by IAChE for at least 3 months.
- psychotropic treatments are tolerated if they were administered and unchanged for at least 3 months
Exclusion Criteria:
- CDR > 2
- Any history or clinical signs of other severe psychiatric illnesses (like major depression,psychosis or obsessive compulsive disorder).
- History of head injury,stroke,or other neurologic disease.
- Organic brain defects on T1 or T2 images.
- History of seizures or unexplained loss of consciousness.
- Implanted pacemaker,medication pump,vagal stimulator,deep brain stimulator.
- Family history of medication refractory epilepsy.
- History of substance abuse within the last 6 months.
Sites / Locations
- Anhui Medical UniversityRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
Cognitive training
Anodal tDCS with Cognitive training
Arm Description
Participants will receive Cognitive training daily for two weeks
Participants will receive anoale tDCS daily and cognitive training for two weeks
Outcomes
Primary Outcome Measures
Memory improved assessed by Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog)
This is an very common clinical motor estimating scale. including orientation, language, structure, application of concepts, immediate recall of words and recognition of words, with a full score of 70. Higher scores indicate worse symptoms.
Secondary Outcome Measures
special-version working memory
the accuracy and reaction time in working memory task
Associative Memory
The changes in Associative Memory will constitute the major research outcome measure used to assess response to HD-tDCS.
MMSE(Mini Mental State Examination)
The full name of MMSE is mini-mental state examination, and the scale consists of 30 subject, include the following seven aspects: time orientation, place orientation,immediate memory,attention and calculation,delay memory,language, visual space.One point is awarded for each question correctly answered during MMSE evaluation. If subject give the wrong answer or don't know answe he/she awarded 0 score, scope of scale score of 0 to 30 points. The higher the score, the better.
LMT (Logic Memory Test)
The changes in LMT will constitute the secondary research outcome
Full Information
NCT ID
NCT04599764
First Posted
October 18, 2020
Last Updated
February 26, 2023
Sponsor
Anhui Medical University
1. Study Identification
Unique Protocol Identification Number
NCT04599764
Brief Title
High Definition Transcranial Direct Current Stimulation (HD-tDCS) for Early Alzheimer's Disease
Acronym
HD-tDCS
Official Title
High Definition Transcranial Direct Current Stimulation (HD-tDCS) for Early Alzheimer's Disease
Study Type
Interventional
2. Study Status
Record Verification Date
February 2023
Overall Recruitment Status
Recruiting
Study Start Date
June 1, 2020 (Actual)
Primary Completion Date
July 1, 2023 (Anticipated)
Study Completion Date
July 1, 2023 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Anhui Medical University
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
To investigate the clinical effect neural mechanism of high-definition transcranial direct current stimulation combined with cognitive training on early AD
Detailed Description
Upon meeting the inclusion criteria and providing informed consent, each participant will complete a series of cognitive assessments and tDCS at the hospital outpatient clinics or inpatient department. Participants were randomly allocated to anode tDCS group with cognitive training, anode tDCS group and the sham group. There are about 20 participants in each group. Participants were studied using a double-blind design. Study participants and all personnel responsible for the effects of the participants remained masked to allocated condition and allocation parameters. Only tDCS administrators had access to the randomization list; they had minimal contact with the participants, and no role in cognitive assessments. For the first 30 participants, allocation was decided by draw. For the subsequent 30 patients, allocation was according to computer generated random numbers. Each participant would be treated for 10 days in two weeks by HD-tDCS.
Before the tDCS, a series of cognitive assessments and neuropsychological tests were obtained by a trained investigator to assess baseline. Each assessment will involve a set of assessment tools, including Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog), Montreal Cognitive Assessment (MoCA) and associative memory as the primary outcome measure and various other tasks and questionnaires to measure cognition(DS, Stroop test, VFT, SDMT), memory (AVLT, AMT, working memory test), emotion(HAMA-17, HAMD-14, eye-tracking technolodgy), executive function(SST, WSCT, GDT) and stimulation tolerability. All the tests are conducted in two days. The participants had receiving a magnetic resonance imaging scan in multi-modalities, and electroencephalography (EEG) record.
Evaluations were conducted one week after treatment and at the end of two weeks of treatment, as well as the Global Index of Safety to assess adverse events of the stimulation. Participants were instructed to focus their answers on the past 7/14 days. The participants had also receiving a battery measure of neuropsychological tests, magnetic resonance imaging scan in multi-modalities, and EEG record. All tests were instructed to finished within 24 hours after the last stimulation. One month and three months after the last stimulation, participants were interviewed to obtain the same assessment as before. They were instructed to focus their answers on the past months.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Transcranial Direct Current Stimulation, Functional Magnetic Resonance Imaging, Early Alzheimer's Disease
Keywords
High Definition Transcranial Direct Current Stimulation, Functional Magnetic Resonance Imaging, Neuropsychology, Early Alzheimer's Disease, Working Memory, Alzheimer's Disease Assessment Scale-Cognitive Subscale
7. Study Design
Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
40 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Cognitive training
Arm Type
Active Comparator
Arm Description
Participants will receive Cognitive training daily for two weeks
Arm Title
Anodal tDCS with Cognitive training
Arm Type
Active Comparator
Arm Description
Participants will receive anoale tDCS daily and cognitive training for two weeks
Intervention Type
Other
Intervention Name(s)
HD-tDCS
Intervention Description
Transcranial direct current stimulation (tDCS) is a non-invasive brain stimulation tool that alters cortical excitability and activity via application of weak direct currents.The respective excitability alterations-enhancement by anodal and reduction by cathodal tDCS-can last for over an hour after the end of stimulation.
Intervention Type
Other
Intervention Name(s)
computer-based cognitive training
Intervention Description
Computer-based cognitive training (CCT) is a potentially important tool for individuals at risk of dementia. Cognitive training in healthy older adults and those at risk of dementia has been linked to benefits in cognitive functioning.
Primary Outcome Measure Information:
Title
Memory improved assessed by Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog)
Description
This is an very common clinical motor estimating scale. including orientation, language, structure, application of concepts, immediate recall of words and recognition of words, with a full score of 70. Higher scores indicate worse symptoms.
Time Frame
changes from baseline at 7,14 days and 4,12 weeks post-treatment
Secondary Outcome Measure Information:
Title
special-version working memory
Description
the accuracy and reaction time in working memory task
Time Frame
changes from baseline at 7,14 days and 4,12 weeks post-treatment
Title
Associative Memory
Description
The changes in Associative Memory will constitute the major research outcome measure used to assess response to HD-tDCS.
Time Frame
changes from baseline at 7,14 days and 4,12 weeks post-treatment
Title
MMSE(Mini Mental State Examination)
Description
The full name of MMSE is mini-mental state examination, and the scale consists of 30 subject, include the following seven aspects: time orientation, place orientation,immediate memory,attention and calculation,delay memory,language, visual space.One point is awarded for each question correctly answered during MMSE evaluation. If subject give the wrong answer or don't know answe he/she awarded 0 score, scope of scale score of 0 to 30 points. The higher the score, the better.
Time Frame
changes from baseline at 7,14 days and 4,12 weeks post-treatment
Title
LMT (Logic Memory Test)
Description
The changes in LMT will constitute the secondary research outcome
Time Frame
changes from baseline at 7,14 days and 4,12 weeks post-treatment
Other Pre-specified Outcome Measures:
Title
DST (Digital Span Test; Forward and Backward)
Description
The changes in DST will constitute the other research outcome.
Time Frame
changes from baseline at 14 days and 4,12 weeks post-treatment
Title
TMT (Trail Making Test)
Description
The Trail Making Test (TMT) is divided into two parts, part A and part B. Part A requires the subject to connect 25 Numbers on the paper in sequence, and part B requires the subject to connect 25 Numbers of different colors alternately in sequence. The time it takes for the subject to complete all the Numbers is the subject's final score.
Time Frame
changes from baseline at 14 days and 4,12 weeks post-treatment
Title
HAMD (Hamilton Depression Scale)
Description
The changes in HAMD will constitute the other research outcome. The examination content consists of 17 questions (about 10 minutes), with a full score of 52. The higher the score, the more severe the depressive symptoms are.
Time Frame
changes from baseline at 14 days and 4,12 weeks post-treatment
Title
HAMA (Hamilton Anxiety Scale)
Description
The changes in HAMD will constitute the other research outcome. The examination content consists of 14 questions (about 10 minutes), with a full score of 56. The higher the score, the more severe the anxiety symptoms are.
Time Frame
changes from baseline at 14 days and 4,12 weeks post-treatment
Title
NPI (Neuropsychiatric Inventory)
Description
The changes in HAMD will constitute the other research outcome.
Time Frame
changes from baseline at 14 days and 4,12 weeks post-treatment
Title
MRI measures
Description
Multimodal magnetic resonance data were acquired, including structural phase magnetic resonance and rest state magnetic resonance.
Time Frame
changes from baseline at 14 days and 4,12 weeks post-treatment
Title
changes in Montreal Cognitive Assessment (MoCA)
Description
MoCA was developed by Nasreddine et al. based on clinical experience and reference to the MMSE cognitive items and scores, and the final version was finalized in November 2004. We adopted a localized version (Mandarin version,includes 2 alternative versions) in line with the Chinese cultural background.It includes 11 inspection items in 8 cognitive fields, including visual structure skills, executive function, naming, attention and calculation, language, abstract thinking, memory, and orientation. With a total score of 30 or more than 26, it is normal. Anyone who has been education for less than 12 years will need to add one point to his final score.
Time Frame
changes from baseline at 14 days and 4,12 weeks post-treatment
Title
GDS(Geriatric depression scale)
Description
The Geriatric Depression Scale (GDS) was created in 1982 by Brank et al. and is dedicated to screening for depression in the elderly. The most suitable feelings for the elderly in the past week were evaluated.There are 30 items in the scale, the total score is 30 points. The higher the score, the more obvious the depressive symptoms. It is generally considered that less than 10 points is normal.
Time Frame
changes from baseline at 14 days and 4,12 weeks post-treatment
Title
JLOT(Judgment of line Judgment of line orientation test orientation test)
Description
The JLOT test was determined by Benton et al. in 1994. There are two versions of H and V. The difference is that the order in which the pictures are presented is different. Each version contains 35 images, of which the official test consists of 30 images, and the other 5 images are for the participants to learn. The final score is the correct number of subjects to answer, the full score is 30 points, the higher the score, the better the space perception ability of the subject.
Time Frame
changes from baseline at 14 days and 4,12 weeks post-treatment
Title
HVOT(Hooper visual organization test Hooper visual organization test)
Description
The changes in HVOT(Hooper visual organization test Hooper visual organization test) will constitute assess response to rTMS the secondary research outcome measure.HVOT is a cognitive test used to evaluate the perceived structure of the subject. It consists of 30 items,and each question is 1 point and the total score is 30 points. The final score is the correct number of subjects to answer, the full score is 30 points, the higher the score, the better the space perception ability of the subject.
Time Frame
changes from baseline at 14 days and 4,12 weeks post-treatment
Title
The Stroop color test
Description
The Stroop color word test was developed by Stroop in 1935 and is used to evaluate the attention function of the subject. The subject is required to correctly read the target color on the stimulus card and record the completion time. The final completion time is the score of the participant. The shorter the time used, the better the performance of the subjects.
Time Frame
changes from baseline at 14 days and 4,12 weeks post-treatment
10. Eligibility
Sex
All
Minimum Age & Unit of Time
50 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Subject diagnosed with early Alzheimer's disease or related diseases according to NINCDS-ACDRADA criteria.
Subjects must have a MMSE score between 10 and 27,indicating mild cognitive impairment or dementia
CDR score ≤ 2
Subject under treatment by IAChE for at least 3 months.
psychotropic treatments are tolerated if they were administered and unchanged for at least 3 months
Exclusion Criteria:
CDR > 2
Any history or clinical signs of other severe psychiatric illnesses (like major depression,psychosis or obsessive compulsive disorder).
History of head injury,stroke,or other neurologic disease.
Organic brain defects on T1 or T2 images.
History of seizures or unexplained loss of consciousness.
Implanted pacemaker,medication pump,vagal stimulator,deep brain stimulator.
Family history of medication refractory epilepsy.
History of substance abuse within the last 6 months.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Kai Wang, PhD
Phone
+86-0551-62922263
Email
wangkai1964@126.com
First Name & Middle Initial & Last Name or Official Title & Degree
Xingqi Wu, M.D.
Phone
18788836237
Ext
+86
Email
wuxingqi09@163.com
Facility Information:
Facility Name
Anhui Medical University
City
Hefei
State/Province
Anhui
ZIP/Postal Code
230032
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Xingqi Wu, M.D.
Phone
+8618788836237
Email
wuxingqi09@163.com
First Name & Middle Initial & Last Name & Degree
Guixian Xiao
Phone
+8617705605378
Email
xiaoguixian1002@126.com
12. IPD Sharing Statement
Learn more about this trial
High Definition Transcranial Direct Current Stimulation (HD-tDCS) for Early Alzheimer's Disease
We'll reach out to this number within 24 hrs